Literature DB >> 25566393

Protothecal peritonitis in child after bone marrow transplantation: case report and literature review of paediatric cases.

T Sykora1, J Horakova1, D Buzzasyova2, M Sladekova3, M Poczova3, S Sufliarska1.   

Abstract

The case presented here illustrates a protothecal infection caused by Prototheca wickerhamii in a paediatric haematopoietic stem cell recipient followed by a review of the literature of all 13 paediatric cases published since 1980. Protothecosis is a rare disease caused by algae, not described in this setting before. Infection was proven additionally post-mortem from peritoneal dialysis fluid. Even though no death of a paediatric patient due to this infection has been reported and the mortality rate associated with protothecosis is low, our patient died from multiorgan failure as a result of numerous post-transplant complications and a strain of cultivated alga that was highly resistant to antifungal agents. Prototheca spp. show various susceptibility profiles, and there is no direct correlation between in vitro activity and clinical response. There are different treatment regimens described but there are no clear published guidelines of specific therapy of protothecosis. Paediatric cases were successfully treated mostly with amphotericin B and azoles. As the number of immunocompromised patients increases, it is necessary to think more about unusual pathogens such as Prototheca.

Entities:  

Keywords:  Bone marrow transplantation; Prototheca wickerhamii; child; peritoneal dialysate; protothecosis

Year:  2014        PMID: 25566393      PMCID: PMC4265046          DOI: 10.1002/nmi2.61

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Case Report

A 3-year-old boy with Philadelphia-chromosome-positive, high-risk acute lymphoblastic leukaemia achieved the first complete remission and underwent allogeneic stem cell transplantation (SCT) from a 10/10 HLA-matched unrelated donor. His conditioning regimen consisted of Fludarabine/Treosulphan/Thiotepa and anti-thymocyte globulin + cyclosporin A as a graft-versus-host disease (GVHD) prophylaxis. The graft was infused after erythrodepletion due to ABO incompatibility. Day +1 after SCT he developed febrile neutropenia. Aetiology of this febrile episode was later identified from a blood culture as Klebsiella pneumoniae and it was treated according to the antibiotic sensitivity tests. In the peri-transplant period he developed a severe veno-occlusive liver disease with high bilirubin blood level, body fluid retention and ascites with the necessity for abdominal drain insertion. Later, anuria and respiratory failure developed and the patient was transferred to the intensive care unit for mechanical ventilation and peritoneal dialysis. Bilirubin blood levels continued to rise up to 857 μmol/L (50.1 mg/dL), a molecular adsorbent recirculation system was used four times. On neutrophil engraftment day +21 the patient's condition had improved—laboratory inflammation markers were decreased as well as fever. On day +26, the intestinal form of GVHD developed with massive intestinal bleeding. Candida fabianii and multiresistant Staphylococcus epidermidis and Enterococcus faecalis were identified as microbial agents causing other concomitant infections (Fig.1).
Figure 1

Course of present case with C reactive protein changes, microbiology findings and antifungal therapy.

Course of present case with C reactive protein changes, microbiology findings and antifungal therapy. Despite 39 days of peritoneal dialysis, the kidney function of the patient did not improve and another febrile episode developed with increased laboratory inflammation markers. Blood cultures and dialysate culture showed multiresistant Stenotrophomonas maltophilia to be the cause of sepsis. Despite intensive and multidisciplinary care the patient died on day +55 after SCT. In addition, the result of dialysate culture revealed a very rare Prototheca wickerhamii. Autopsy was not performed.

Discussion

Prototheca spp. are ubiquitous chlorophyllous algae belonging to the Chlorophyceae. Besides various environmental niches, Prototheca spp. have been found colonizing the human skin, fingernails and respiratory and digestive systems 1. It is not a common hospital-borne infection. Hospital-acquired cases have been associated with surgery and orthopaedic procedures, but human-to-human transmission has not been reported 1. The source of the infection in this case is unknown. Five species of Prototheca have been distinguished, of which only two—P. wickerhamii and Prototheca zopfii—are described as pathogenic in humans 1. In the present case white and pale cream-coloured yeast-like colonies were grown on Sabouraud dextrose agar with antibiotics after 5 days of incubation at 30°C. Direct microscopy showed large Gram-positive cells of various sizes resembling yeast-like formations but budding was absent (Fig.2). Further micromorphological and biochemical description was made with identification of the strain as P. wickerhamii.
Figure 2

Microscopic and cultivation results. (a) Direct microscopy of large cells resembling yeast-like formation without budding (× 200 magnification). (b) White and pale cream-coloured yeast-like colonies on Sabouraud dextrose agar.

Microscopic and cultivation results. (a) Direct microscopy of large cells resembling yeast-like formation without budding (× 200 magnification). (b) White and pale cream-coloured yeast-like colonies on Sabouraud dextrose agar. According to animal experiments, Prototheca spp. seem to have low virulence, overall their pathogenicity is moderate and protothecosis is considered a rare opportunistic infection 2,3. According to the clinical presentation, there are three distinguished clinical forms known—cutaneous infection, bursitis and systemic infection. The most common are cutaneous infection and olecranon bursitis; systemic dissemination or organ involvement represents only 10% of all reported infections 4. Previous review studies suggested a 2.2% attributable mortality rate, which represents a lower number compared with candidaemia, but individual outcome still depends on the history and clinical context of each patient 5. Among all patients with cancer and protothecosis, overall mortality was 54% and attributable mortality was 14% 6. Patients who are immunocompromised due to steroid use or who have underlying haematological/solid malignancy or AIDS have a higher risk of protothecosis. More than 120 cases of protothecosis have been reported and it is believed that a much greater number of cases are unreported, perhaps because of morphological confusion with other microbes such as Lacazia lobii, Coccidio desimmitis, Histoplasma duboisii, Blastomyces dermatitis or Pneumocystis jirovecii 7. Protothecosis in children mostly presents as infections involving various organs. From the 13 cases reported five were cutaneous, with or without olecranon bursitis, one was a catheter-related infection and the rest had other organ involvement (Table1). Generally, Prototheca spp. show various susceptibility profiles, and there is no direct correlation between in vitro activity and clinical response 1. There are no published guidelines of specific treatments for protothecosis. Algae are susceptible to amphotericin B and most of them were resistant to 5-flucytosine, fluconazole and itraconazole 5. In contrast to this, voriconazole shows superior activity against P. wickerhamii 1. In the case described here, the P. wickerhamii strain was fully susceptible only to amphotericin B, voriconazole was not effective (Table2). Paediatric cases were successfully treated mostly by amphotericin B and azoles (Table1). From review papers it can generally be concluded that most failures are associated with monotherapy by azoles 1. The therapeutic response of paediatric patients to amphotericin B treatment is very good, even though the optimal dosage and duration of an antifungal therapy are unknown. The only death of a child with protothecosis reported is our present patient. Antifungal treatment and prophylaxis of our patient followed the SCT guidelines using micafungin antimycotic prophylaxis. Changes of anti-infective agents followed the recommendations of the European Society for Blood and Marrow Transplantation guidelines according to the current clinical status and microbial finding in the patient (Fig.1). However, the anti-infective management was very challenging because of the kidney failure and other post-transplantation complications.
Table 1

Review of 13 paediatric cases of protothecosis published since 1980

Patient no.Age/sexMedical historySite/organ involvementDiagnosisTreatmentOutcomeReference
17 years/MHodgkin's lymphomaCatheter tipCulture P. wickerhamiiCatheter removalAm BCureLeimann et al., 2004 (Heney et al., 1991)
217 years/FSurgery, ganglion removalHand abscessCulture P. wickerhamiiMultiple excisionsCureLeimann et al., 2004 (Iacoviello et al., 1992Holcomb, 1981a)
38 months/?UnlistedGastroenteritisCulture P. wickerhamiiNoneUnlistedLeimann et al., 2004(Iacoviello et al., 1992Casal, 1983a)
46 years/FUnlistedVulvaCulture P. wickerhamiiGentian violet, steroidsCureLeimann et al., 2004 (Iacoviello et al., 1992Nelson, 1987a)
55 years/FUnlistedUpper lipCulture P. wickerhamiiKetoconazoleGood responseLeimann et al., 2004 (Iacoviello et al., 1992Kuo, 1987a)
615 years/MUnlistedSmall intestine, liverHistopathology and culture P. wickerhamiiAm B + fluconazoleUnlistedLeimann et al., 2004 (Ravisse et al., 1993Matsuda, 1991b)
713 years/MAnaemiaSmall intestine + lymph nodesHistopathology and culture P. wickerhamiiAm BUnlistedLeimann et al., 2004 (Ravisse et al., 1993Matsuda, 1991b)
878 days/MVery low birthweightEndocarditisHistopathology and culture P. wickerhamiiResection of atrium massAm BCureLeimann et al., 2004 (Buendra et al., 1999)
910 years/MCombined immunodeficiencySkin + olecranon bursitisCulture P. wickerhamiiAm B + itraconazoleIVIGGood responseMathew et al., 2010
106 months/MCongenital hydrocephalusCentral nervous systemMicroscopy and molecular identificationKetoconazoleFluconazole + Am BCureZak et al., 2012
1114 years/MUnlistedSkinMicroscopy and culture Prototheca spp.ItraconazoleCureKalsy et al., 2012
124 years/FLiver transplantation, immunosuppressionLungsCulture P. wickerhamiiAm BCureTan et al., 2013
132 years/FSubmental and foot abscessSkinMicroscopy identificationAm B + gentamicinItraconazoleCureTello–Zavala et al., 2013
143 years/MALL Ph+, MUD BMT, multiorgan failurePeritoneal dialysateCulture P. wickerhamiiNoneDeathHere presented

References from Table1: Leimann et al., 2004 4; Heney et al., 1991 8; Iacoviello et al., 1992 9; Ravisse et al., 1993 10; Buendra et al., 1998 11; Mathew et al., 2010 12; Zak et al., 2012 13; Kalsy et al., 2012 14; Tan et al., 2013 15; Tello-Zavala et al., 2013 16. Am B, amphotericin B; ALL Ph+, positive high-risk acute lymphoblastic leukaemia; IVIG, intravenous immunoglobulin; MUD BMT, unrelated matched donor bone marrow transplantation.

Cases mentioned and referred to in Iacoviello's review (1992).

Cases mentioned and referred to in Ravisse's review (1993).

Table 2

Minimal inhibition concentration profile of Prototheca wickerhamii strain cultivated in the present case

Antifungal agentDosage (mg/L)Susceptibility
Voriconazole32.0Resistant
Posaconazole2.0Susceptible only to higher dosage
Amphotericin B0.094Susceptible
Fluconazole256.0Resistant
Itraconazole32.0Resistant
Echinocandins (micafungin, anidulafungin, caspofungin)32.0Resistant
Review of 13 paediatric cases of protothecosis published since 1980 References from Table1: Leimann et al., 2004 4; Heney et al., 1991 8; Iacoviello et al., 1992 9; Ravisse et al., 1993 10; Buendra et al., 1998 11; Mathew et al., 2010 12; Zak et al., 2012 13; Kalsy et al., 2012 14; Tan et al., 2013 15; Tello-Zavala et al., 2013 16. Am B, amphotericin B; ALL Ph+, positive high-risk acute lymphoblastic leukaemia; IVIG, intravenous immunoglobulin; MUD BMT, unrelated matched donor bone marrow transplantation. Cases mentioned and referred to in Iacoviello's review (1992). Cases mentioned and referred to in Ravisse's review (1993). Minimal inhibition concentration profile of Prototheca wickerhamii strain cultivated in the present case Protothecal infection usually runs with other co-pathogens such as cytomegalovirus, herpes simplex virus, Staphyloccocus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Cryptococcus spp., Candida glabrata and Aspergillus spp. 1. In the present case different co-pathogens were identified: Gram-negative bacterium Stenotrophomonas maltophilia and Candida fabianii (Fig.1). Cytomegalovirus, Epstein–Barr virus, adenovirus and BK virus infections repeatedly tested negative on PCR. Besides viruses, mannan, anti-mannan and galactomannan antigen testing was run for complete mycology follow up. Microbiological tests were performed routinely every 3–4 days; collection of specimens was performed in sterile conditions. Infection developed on caspofungin, meropenem and acyclovir. Amphotericin B appears to be the most effective drug for systemic protothecosis, although it has been reported to be ineffective in some cases. So far it is recommended as the first-line therapy in cases of dissemination and for patients who are severely immunocompromised, or have other underlying illness 17. This recommendation was irrelevant for our patient because of the kidney failure that did not improve. Duration of microbial identification in our settings is approximately 4 days. The results of the cultures from the peritoneal dialysate were obtained after the patient had died. It is evident that the unstable and critical condition of the patient played a key role in his death and the protothecal infection was only a contributory factor. Regarding the source of infection, the reported data of protothecosis in patients with long-lasting peritoneal dialysis showed that the catheter was infected. In the case described here, the peritoneal catheter was replaced 1–2 days before death, due to its malfunction and clogging with blood coagula. We have no evidence of contaminated surgical equipment during the handling procedure. Previous peritoneal dialysates tested negative; this was the only positive specimen. After the identification of P. wickerhamii, a sample of the alga was deposited in the mycology laboratory archives. According to published data, this is the first reported case of protothecosis in a paediatric bone marrow transplantation recipient. There is a rising probability of infection by less common and more atypical infectious organisms. Prototheca is a rare pathogen and so is not usually suspected. As the number of immunocompromised patients increases, it is necessary to think more of unusual pathogens when it comes to diagnosis of infectious complications during treatment.
  12 in total

Review 1.  Protothecosis.

Authors:  Sara M Kantrow; Alan S Boyd
Journal:  Dermatol Clin       Date:  2003-04       Impact factor: 3.478

2.  Disseminated protothecosis in a Mexican child.

Authors:  María Concepción Tello-Zavala; Araceli Mercado-Lara; Nadia Gómez-Hernández; Veronica Recio-Martinez
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

Review 3.  Systemic chlorellosis, an emerging infection in humans caused by algae.

Authors:  V Krcméry
Journal:  Int J Antimicrob Agents       Date:  2000-08       Impact factor: 5.283

4.  Phagocytosis and algicidal activity of human polymorphonuclear neutrophils against Prototheca wickerhamii.

Authors:  J P Phair; J E Williams; H P Bassaris; C R Zeiss; B A Morlock
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

Review 5.  Protothecosis complicating prolonged endotracheal intubation: case report and literature review.

Authors:  V R Iacoviello; P C DeGirolami; J Lucarini; K Sutker; M E Williams; C A Wanke
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

Review 6.  Protothecosis.

Authors:  Beatriz Consuelo Quinet Leimann; Paulo Cezar Fialho Monteiro; Márcia Lazéra; Eduardo R Ulloa Candanoza; Bodo Wanke
Journal:  Med Mycol       Date:  2004-04       Impact factor: 4.076

7.  Protothecosis in patients with cancer: case series and literature review.

Authors:  H A Torres; G P Bodey; J J Tarrand; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2003-08       Impact factor: 8.067

Review 8.  Human protothecosis.

Authors:  Cornelia Lass-Flörl; Astrid Mayr
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

9.  Prototheca wickerhamii as a cause of neuroinfection in a child with congenital hydrocephalus. First case of human protothecosis in Poland.

Authors:  Iwona Zak; Tomasz Jagielski; Stanisław Kwiatkowski; Jacek Bielecki
Journal:  Diagn Microbiol Infect Dis       Date:  2012-08-02       Impact factor: 2.803

10.  Disseminated protothecosis.

Authors:  Leni G Mathew; Susanne Pulimood; Meera Thomas; Mary A Acharya; Promila Mohan Raj; Mary S Mathews
Journal:  Indian J Pediatr       Date:  2010-02       Impact factor: 5.319

View more
  2 in total

1.  Successful treatment of cutaneous protothecosis with liposomal amphotericin and oral itraconazole.

Authors:  Brendan McMullan; Simon Pollett; Chayanika Biswas; Donald Packham
Journal:  Med Mycol Case Rep       Date:  2016-08-03

2.  3-Bromopyruvate as an Alternative Option for the Treatment of Protothecosis.

Authors:  Tomasz Jagielski; Katarzyna Niedźwiecka; Katarzyna Roeske; Mariusz Dyląg
Journal:  Front Pharmacol       Date:  2018-04-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.